- In April 2025, GSK plc reported positive results for Nucala (mepolizumab) in treating chronic obstructive pulmonary disease (COPD), with the complete findings from the MATINEE phase III trial published in the New England Journal of Medicine. The trial assessed mepolizumab, a monoclonal antibody targeting interleukin-5 (IL-5), in a diverse group of COPD patients. Across the entire study population, mepolizumab demonstrated a clinically meaningful and statistically significant 21% reduction in the annualized rate of moderate/severe exacerbations compared to placebo, successfully meeting the primary endpoint of the MATINEE trial
- In December 2024, GSK plc announced positive results for Nucala (mepolizumab) in the treatment of chronic obstructive pulmonary disease (COPD), with the full findings from the MATINEE phase III trial published in the New England Journal of Medicine. The trial assessed mepolizumab, a monoclonal antibody targeting interleukin-5 (IL-5), in a broad range of COPD patients, including those with the most severe and hard-to-treat forms, as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Nucala is currently approved for use in the U.S. for four IL-5 mediated conditions
- In January 2024, GSK plc announced that the China National Medical Products Administration (NMPA) had approved Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older. This marks Nucala as the first anti-Interleukin-5 (IL-5) targeting treatment to receive approval in China for use in adult and adolescent patients with this condition
- In July 2021, GlaxoSmithKline plc (GSK) announced that the U.S. Food and Drug Administration (FDA) had approved Nucala (mepolizumab), a monoclonal antibody targeting interleukin-5 (IL-5), as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). This approval provides a new indication for mepolizumab as an add-on maintenance treatment for adult patients aged 18 and older with CRSwNP who have not responded adequately to nasal corticosteroids
